1Thomas A. Wynn. Common and unique mechanisms regulatefibrosis in various fibro proliferative diseases [J]. The Journal of Clinical Investigation , 2007 ,117 ( 3 ) : 524- 529.
2YOUHUA LIU. Epithelial to Mesenchymal Transition in Renal Fibrogenesis:Pathologic Significance, Molecular Mechanism,and Therapeutic Intervention[J]. J Am Soc Nephrol, 2004,15 : 1-12.
3Andras Masszi, Ling zhi Fan, Christopher A, et al. Integrity of Cell-Cell Contacts Is a Critical Regulator of TGF-β1 Induced Epithelial-to-Myofibroblast Transition Role for β-Catenin[J]. Am J Pathol, 2004,165 (6) : 1955-1967.
4Neil G. Docherty. TGF-β1 induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation [J]. Am J Physiol Renal Physiol,2006,290(5) :F1202- F1212.
5Phanish MK, Wahab NA, Colville Nash P, et al. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotie TGF-β1 responses in human proximal-tubule epithelial cells [J]. Biochem J, 2006,393 (10) : 601-607.
6Jun wei Yang,Chun sun Dai, You hua Liu. A Novel Mechanism by which Hepatocyte Growth Factor Blocks Tubular Epithelial to Mesenchymal Transition[J]. J Am Soc Nephrol,2005,16(10) :68- 78.
7Jurgen J. W. Mulsow, AFRCSI, R. William G. Watson, et al. Transforming Growth Factor-β Promotes Pro-fibrotic Behavior by Serosal Fibroblasts via PKC and ERK1/2 Mitogen Activated Protein Kinase Cell Signaling [J]. Ann Surg, 2005,242 (6) : 880- 889.
8Bradford C. Berk,Keigi Fujiwara, Stephanie Lehoux. ECM remod eling in hypertensive heart disease [J]. J Clin Invest, 2007,117 (3): 568-575.
9Cancilla B,Davies A,Cauehi JA,et al. Fibroblast growth factor receptors and their ligands in the adult rat kidney[J]. Kidney Int, 2001,60(1) : 147-155.
10Clayton A, Thomas J,Thomas D J, et al. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2 [J]. Kidney Int, 2001,59 (6) : 2084-2094.
二级参考文献1
1D. Montgomery Bissell. Hepatic fibrosis as wound repair: A progress report[J] 1998,Journal of Gastroenterology(2):295～302
1Sinha M, John KR, Chacko KN, et al. A cost comparison of open versus percutaneous approaches to management of large staghom calculi [ J ]. Indian J Urol,2008,24( 1 ) :28-34.
2Losek RL, Mauro LS. Efficacy of tamsulosin with extracorporeal shock wave lithotripsy for passage of renal and ureteral calculi [ J ]. Ann Pharmacother,2008,42 ( 5 ) :692-697.
3Mohammadi-Karakani A, Asgarzadeh-Haghighi S, Gha-zi-khansari M, et al. Determination of urinary enzymes as a markers of early renal damage in diabetic patients [ J ]. J Clin Lab Anal, 2007,21 ( 6 ) : 413- 417.
4KalanSooriya A, Jenningsp, Haddad F, et al. Urinary enzyme measure- ments as early indicators of renal insult in type diabetes[ J]. Br J Bi- omed SCI,2007,64(4) : 153-156.
5Gressner AM, Weiskirchen R. Modem pathogenetic concepts of liver fi- brosis suggest stellate cells and TGF-beta as major players and thera- peutic targets[ J]. J Cell Mol Med,2006,10( 1 ) :76-99.
6Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transfoming growth factor-beta type I receptor kinase ( ALK5 ) inhibitor, suppresses renal fibrosis in obstructive nephropathy[ J ].Kidney Int,2006 (70) :1234- 1243.
7Hwang M, Kim H J, Noh HJ, et al. TGF-beta I siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction [ J ]. Exp Mol Pathol,2006,81 ( 1 ) :48-54.
